Thromb Haemost 2009; 101(02): 317-324
DOI: 10.1160/TH08-06-0411
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Association study between variants in the fibrinogen gene cluster, fibrinogen levels and hypertension: Results from the MONICA/ KORA study

Melanie Kolz
1   Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany
,
Jens Baumert
1   Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany
,
Henning Gohlke
1   Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany
,
Harald Grallert
1   Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany
,
Angela Döring
1   Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany
,
Annette Peters
1   Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany
,
Erich H. Wichmann
1   Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany
2   IBE, Chair of Epidemiology, University of Munich, Germany
,
Wolfgang Koenig
3   Department of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany
,
Thomas Illig
1   Institute of Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany
› Author Affiliations
Financial support: The MONICA/KORA Augsburg cohort study was financed by the Helmholtz Zentrum München and supported by grants from the German Ministry of Education and Research (BMBF)/National Genome Research Network (NGFN).
Further Information

Publication History

Received: 26 June 2008

Accepted after minor revision: 19 January 2008

Publication Date:
23 November 2017 (online)

Summary

Previous studies reported a gender-specific association between plasma fibrinogen concentrations and incident hypertension. We systematically analysed polymorphisms and haplotypes across the fibrinogen gene cluster with fibrinogen levels and assessed their contribution to prevalent hypertension in 2,200 men and 2,159 women from the population-based MONICA/KORA Augsburg study. Eleven tagging single nucleotide polymorphisms (SNPs) were systematically selected in the three fibrinogen genes and haplotypes were reconstructed. The minor alleles of two SNPs, rs2227401 (FGB) and rs2070016 (FGA) and the haplotypes tagged by those variants, were significantly associated with higher fibrinogen concentrations in both, men and women, explaining 1% of the total variance of fibrinogen concentrations. In addition, a FGG haplotype, tagged by rs1049636, was associated with lower concentrations of fibrinogen in women, but not in men. Regarding hypertension, we detected a significant association with a FGA promoter variant (rs2070008) in women only, whereas fibrinogen haplotypes were not associated with hyper-tension after correction for multiple comparisons in either men or women. In conclusion, our results suggest that variants in all three fibrinogen genes are significantly associated with differences in fibrinogen concentrations with modest contribution to phenotypic variance. It is likely that other genetic variants outside the fibrinogen gene loci are involved in the regulation of fibrinogen concentrations. In addition, one FGA promoter variant was significantly associated with hypertension in women. Confirmation of these findings by future studies is warranted.

 
  • References

  • 1 Schneider DJ, Taatjes DJ, Howard DB. et al. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glyco-protein: a potential contributor to cardiovascular risk. J Am Coll Cardiol 1999; 33: 261-266.
  • 2 Koenig W, Ernst E. The possible role of hemorheology in atherothrombogenesis. Atherosclerosis 1992; 94: 93-107.
  • 3 Nesbitt JE, Fuller GM. Transcription and translation are required for fibrinogen mRNA degradation in hepatocytes. Biochim Biophys Acta 1991; 1089: 88-94.
  • 4 Yu S, Sher B, Kudryk B. et al. Fibrinogen precursors. Order of assembly of fibrinogen chains. J Biol Chem 1984; 259: 10574-10581.
  • 5 Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 2003; 89: 601-609.
  • 6 de Lange M, de Geus EJ, Kluft C. et al. Genetic influences on fibrinogen, tissue plasminogen activator-antigen and von Willebrand factor in males and females. Thromb Haemost 2006; 95: 414-419.
  • 7 Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann NY Acad Sci 2001; 936: 549-559.
  • 8 Iacoviello L, Vischetti M, Zito F. et al. Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001; 38: 1199-1203.
  • 9 Carty CL, Cushman M, Jones D. et al. Associations between common fibrinogen gene polymorphisms and cardiovascular disease in older adults. The Cardiovascular Health Study. Thromb Haemost 2008; 99: 388-395.
  • 10 Mannila MN, Eriksson P, Lundman P. et al. Contribution of haplotypes across the fibrinogen gene cluster to variation in risk of myocardial infarction. Thromb Haemost 2005; 93: 570-577.
  • 11 Reiner AP, Carty CL, Carlson CS. et al. Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Thromb Haemost 2006; 4: 1279-1287.
  • 12 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ. et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma’ levels. Blood 2005; 106: 4176-4183.
  • 13 Danesh J, Lewington S, Thompson SG. et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. J Am Med Assoc 2005; 294: 1799-1809.
  • 14 Behague I, Poirier O, Nicaud V. et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude CasTemoins sur l‘Infarctus du Myocarde. Circulation 1996; 93: 440-449.
  • 15 Kardys I, Uitterlinden AG, Hofman A. et al. Fibrinogen gene haplotypes in relation to risk of coronary events and coronary and extracoronary atherosclerosis: the Rotterdam Study. Thromb Haemost 2007; 97: 288-295.
  • 16 Lawlor DA, Smith GD, Rumley A. et al. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. British Women’s Heart and Health Study. Thromb Haemost 2005; 93: 955-963.
  • 17 Folsom AR, Peacock JM, Nieto FJ. et al. Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens 1998; 16: 1579-1583.
  • 18 Shankar A, Wang JJ, Rochtchina E. et al. Positive association between plasma fibrinogen level and incident hypertension among men: population-based cohort study. Hypertension 2006; 48: 1043-1049.
  • 19 Lee AJ, Lowe GD, Woodward M. et al. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J 1993; 69: 338-342.
  • 20 Eliasson M, Evrin PE, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47: 513-524.
  • 21 Green D, Ruth KJ, Folsom AR. et al. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb 1994; 14: 686-693.
  • 22 Fowkes FG, Lowe GD, Rumley A. et al. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur. Heart J 1993; 14: 597-601.
  • 23 Wichmann HE, Gieger C, Illig T. KORA-gen--resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 2005; 67 (Suppl. 01) S26-S30.
  • 24 Lowel H, Doring A, Schneider A. et al. The MONICA Augsburg surveys--basis for prospective cohort studies. Gesundheitswesen 2005; 67 (Suppl. 01) S13-S18.
  • 25 Rathmann W, Haastert B, Icks A. et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46: 182-189.
  • 26 Kirkendall WM, Feinleib M, Freis ED. et al. Recommendations for human blood pressure determination by sphygmomanometers. Subcommittee of the AHA Postgraduate Education Committee. Hyper-tension 1981; 3: 510A-519A.
  • 27 Hense HW, Kuulasmaa K, Zaborskis A. et al. Quality assessment of blood pressure measurements in epidemiological surveys. The impact of last digit preference and the proportions of identical duplicate measurements. WHO Monica Project. Rev Epidemiol Sante Publique 1990; 38: 463-468.
  • 28 Weidinger S, Klopp N, Wagenpfeil S. et al. Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults. J Med Genet 2004; 41: 658-663.
  • 29 Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995; 12: 921-927.
  • 30 Wang N, Akey JM, Zhang K. et al. Distribution of recombination crossovers and the origin of haplotype blocks: the interplay of population history, recombination, and mutation. Am J Hum Genet 2002; 71: 1227-1234.
  • 31 Verschuur M, de Jong M, Felida L. et al. A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent –148C/T polymorphism. J Biol Chem 2005; 280: 16763-16771.
  • 32 Brown ET, Fuller GM. Detection of a complex that associates with the Bbeta fibrinogen G-455-A polymorphism. Blood 1998; 92: 3286-3293.
  • 33 Lovely RS, Falls LA, Al Mondhiry HA. et al. Association of gammaA/gamma’ fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88: 26-31.